Research programme: hepatitis C virus protease and polymerase inhibitors - Novartis/Medivir

Drug Profile

Research programme: hepatitis C virus protease and polymerase inhibitors - Novartis/Medivir

Latest Information Update: 05 Jun 2007

Price : $50

At a glance

  • Originator Medivir AB
  • Developer Medivir AB; Novartis
  • Class
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 22 Jul 2004 This programme is still in active development
  • 07 Sep 2001 Preclinical development for Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top